News | June 10, 2022
GE Healthcare’s molecular imaging solutions enable precision health & theranostics for prostate cancer
Healthcare is timely and personal – and its delivery should be too
Healthcare is timely and personal – and its delivery should be too
The HALO Prostate AI algorithm deployed in HALO AP from Indica Labs
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
Last year, the company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation
These results will be presented on 17 February at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
The collaboration will see HNL Lab Medicine deploy Ibex’s cutting-edge AI solution, Ibex Prostate, for biopsies and transurethral resection of the prostate (TURP), boosting both diagnostic accuracy and workflow efficiency
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
The move strengthens GBL’s clinical-stage presence in the United States
Subscribe To Our Newsletter & Stay Updated
